source
- FDA advisory panel to consider reclassifying several widely used peptidesAn FDA advisory committee is meeting this week to decide whether it will recommend reclassifying a group of popular peptide products. The discussion comes as the industry watches closely for any sh…
- Crystalys mines $130M series B to push gout drug through phase 3Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.